Neonatal Respiratory Distress Syndrome Treatment Market Set for Strong Growth Driven by Rising Premature Births and Advances in Neonatal Respiratory Care

Neonatal Respiratory Distress Syndrome Treatment Market Overview

The Neonatal Respiratory Distress Syndrome Treatment Market is witnessing steady growth as healthcare systems expand neonatal intensive care capabilities and improve treatment options for premature infants. According to Maximize Market Research, the market was valued at USD 778.2 million in 2022 and is expected to grow at a CAGR of 7.5% from 2023 to 2029, reaching approximately USD 1,291.07 million by 2029. Neonatal respiratory distress syndrome (NRDS) primarily affects premature newborns whose immature lungs do not produce sufficient surfactant, resulting in breathing difficulties and the need for specialized respiratory support. 

The rising incidence of premature births remains a major growth driver. Increasing availability of neonatal intensive care units, advances in surfactant replacement therapy, oxygen therapy, mechanical ventilation, and non-invasive respiratory support are also supporting market expansion. The growing adoption of minimally invasive surfactant administration (MIST) represents a particularly important opportunity because it can provide surfactant while reducing reliance on invasive ventilation. 

Technological progress in neonatal respiratory care is creating additional opportunities. Non-invasive ventilation technologies such as nasal continuous positive airway pressure (CPAP) and high-flow nasal cannula (HFNC) are gaining importance, while personalized treatment approaches and biomarker-based diagnosis could improve treatment selection. However, high treatment costs, limited access to specialized neonatal care in developing regions, and complications associated with invasive ventilation remain significant challenges.

* Download the Full Market Report: https://www.maximizemarketresearch.com/request-sample/211019/ 

US Market Trends and Investment

The United States remains a leading market because of its established healthcare infrastructure, advanced neonatal intensive care facilities, research capabilities, and availability of specialized respiratory technologies. In 2025, Beyond Air submitted a PMA supplement to the U.S. Food and Drug Administration for its LungFit PH 2 nitric-oxide delivery system. The lighter, transport-ready system is designed to provide continuous nitric oxide delivery while improving portability for patients requiring respiratory support, including neonatal applications. At the pharmaceutical level, AbbVie announced a $195 million investment in August 2025 to expand active pharmaceutical ingredient manufacturing capacity at its North Chicago facility, as part of its broader U.S. manufacturing investment strategy. These developments reflect continuing US investment in advanced respiratory technologies, pharmaceutical manufacturing, and specialized neonatal care.

Market Segmentation

According to the supplied Maximize Market Research report, the market is segmented by Therapy, End User, and Region. By therapy, Surfactant Therapy holds a significant share of the market because surfactant replacement is an established treatment for premature infants with inadequate natural surfactant production. Exogenous surfactants improve lung function and help reduce complications associated with respiratory distress. Mechanical ventilation is also widely used in severe cases where infants require additional respiratory support. 

The report categorizes therapy into Oxygen Therapy, Surfactant Therapy, and Other. By end user, the market is segmented into Hospitals, Sub-acute Facilities, Home Care, Retail Pharmacies, and Other. Hospitals and specialized neonatal facilities remain central to treatment because NRDS frequently requires immediate respiratory intervention and intensive monitoring. 

Neonatal respiratory distress syndrome treatment Market, Key Players are
1. AbbVie Inc. (United States)
2. Chiesi Farmaceutici S.p.A. (Italy)
3. Merck & Co., Inc. (United States)
4. ONY, Inc. (United States)
5. Novartis AG (Switzerland)
6. Pfizer Inc. (United States)
7. Drägerwerk AG & Co. KGaA (Germany)
8. Fisher & Paykel Healthcare Limited (New Zealand)
9. Hamilton Medical AG (Switzerland)
10. Getinge AB (Sweden)
11. Medtronic plc (Ireland)
12. Philips Healthcare (Netherlands)
13. Masimo Corporation (United States)
14. Vyaire Medical Inc. (United States)
15. GE Healthcare (United States)
16. Smiths Medical (United Kingdom)
17. Teleflex Incorporated (United States)
18. Becton, Dickinson, and Company (United States)
19. Hill-Rom Holdings, Inc. (United States)
20. ResMed Inc. (United States)

* Download the Full Market Report: https://www.maximizemarketresearch.com/request-sample/211019/ 

Competitive Analysis

The MMR report identifies AbbVie Inc., Chiesi Farmaceutici S.p.A., Merck & Co., Inc., ONY Inc., Novartis AG, Pfizer Inc., Drägerwerk AG & Co. KGaA, Fisher & Paykel Healthcare, Hamilton Medical, Getinge, Medtronic, Philips Healthcare, Masimo, Vyaire Medical, GE Healthcare, Teleflex, Becton Dickinson, ResMed, and other companies as key market participants. The publicly available report does not disclose individual percentage market shares or a verified top-five ranking, so assigning specific market-share positions would require unsupported estimates. 

Chiesi Farmaceutici is particularly important in neonatal respiratory care through its Curosurf surfactant franchise. The company continued investing heavily in respiratory and neonatology innovation during 2025. Chiesi reported €409 million in R&D investment during the first half of 2025, representing 22% of revenue, while its neonatology pipeline includes research into less-invasive targeted delivery of Curosurf to infant lungs.

AbbVie remains one of the pharmaceutical companies identified in the MMR competitive landscape and expanded US manufacturing capacity in 2025 through its $195 million North Chicago investment. This type of manufacturing expansion can strengthen pharmaceutical supply capabilities and support future treatment development. 

Drägerwerk contributes advanced neonatal ventilation and respiratory-care equipment, supporting hospitals seeking reliable respiratory support systems for premature infants. Fisher & Paykel Healthcare is another important participant, with technologies focused on respiratory support and neonatal respiratory interfaces.

Medtronic participates through respiratory and critical-care technologies, while its broad medical-device portfolio provides opportunities to integrate improved respiratory support, monitoring, and ventilation technologies into neonatal care environments. These companies collectively contribute to innovation in ventilation, oxygen delivery, monitoring, and respiratory treatment.

Regional Analysis

North America dominated the Global Neonatal Respiratory Distress Syndrome Treatment Market, supported by well-established healthcare infrastructure, high awareness of neonatal care, advanced medical technologies, and government and research support. The presence of pharmaceutical companies, medical-device manufacturers, research institutions, and specialized neonatal intensive care units further strengthens the region's position.

The United States is the principal contributor to North America's market position. Advanced NICU infrastructure and access to surfactant therapies, ventilation systems, oxygen-delivery technologies, and specialized neonatal physicians support demand. Continued investment in respiratory technologies is also creating opportunities for more portable and less-invasive treatment solutions.

Europe represents another significant market, supported by advanced neonatal facilities, government healthcare programs, and emphasis on early diagnosis and specialized treatment. The UK, Germany, and France benefit from established healthcare systems and sophisticated neonatal-care infrastructure. Meanwhile, Japan and China offer important opportunities in Asia because of expanding healthcare capabilities and investments in specialized neonatal services. The MMR report does not provide individual percentage market shares for these countries, so specific country-level shares are not stated.

Conclusion

The Global Neonatal Respiratory Distress Syndrome Treatment Market is positioned for sustained expansion, with revenue projected to increase from USD 778.2 million in 2022 to USD 1,291.07 million by 2029 at a 7.5% CAGR. Rising premature births, improving neonatal intensive care infrastructure, and advances in surfactant and respiratory-support technologies will remain the principal market drivers.

In our view, the strongest opportunities will come from minimally invasive surfactant administration, advanced synthetic and natural surfactants, non-invasive ventilation, portable respiratory-support systems, and improved neonatal monitoring technologies. Reducing treatment complications while making advanced respiratory care more accessible will be particularly important. Companies that combine clinical effectiveness, ease of use, portability, and cost efficiency can play a major role in expanding access to life-saving neonatal respiratory treatment worldwide.

About Maximize Market Research

Maximize Market Research Pvt. Ltd. (MMR) is a global market research and consulting firm known for delivering accurate, actionable, and data-driven insights. Our expertise spans diverse industries — including medical devices, pharmaceuticals, technology, automotive, electronics, chemicals, personal care, and consumer goods. We provide services such as market-validated forecasts, competitive intelligence, strategic consulting, and industry impact analysis, helping businesses navigate market complexities and achieve sustainable growth.

Contact Maximize Market Research

MAXIMIZE MARKET RESEARCH PVT. LTD.
2nd Floor, Naval IT Park Phase 3,
Pune-Bangalore Highway, Narhe,
Pune, Maharashtra 411041, India.
📞 +91 9607365656
📧 sales@maximizemarketresearch.com